Saccharomyces boulardii için Clostridioides difficile Infection (CDI)

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Sonuç

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

Key Study Findings

Review

The evidence for probiotics in the treatment of digestive disorders in the pediatric population.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: Pediatric population

Review

Clostridioides difficile Infections: Prevention and Treatment Strategies.

Dose: None vs: None Outcome: C. difficile infection treatment outcomes Etki: None None

Popülasyon: Patients with C. difficile infection

Review 520 weeks

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: None

Review

Clostridium difficile Colitis Prevention and Treatment.

Dose: None vs: None Outcome: Diarrhea outcomes Etki: None None

Popülasyon: None

Systematic Review n=228

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.

Dose: None vs: None Outcome: Diarrhea outcomes Etki: None None

Popülasyon: None

Review

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?

Dose: None vs: None Outcome: GI condition outcomes (C. diff, AAD, H. pylori) Etki: None None

Popülasyon: Adults with GI conditions

Key Statistics

Çalışmalar

3000

Katılımcılar

↑

Positive

Derece

Referenced Papers

The evidence for probiotics in the treatment of digestive disorders in the pediatric population. Review

Journal of gastroenterology … 2025 10 atıf

Clostridioides difficile Infections: Prevention and Treatment Strategies. Review

Advances in experimental … 2024 2 atıf

Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea. Review

Cureus 2023 5 atıf

Clostridium difficile Colitis Prevention and Treatment. Review

Advances in experimental … 2019 17 atıf

Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Other

Frontiers in medicine 2018 450 atıf

Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Review

Pharmacological research 2018 132 atıf

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Review

The American journal … 2018 46 atıf

Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. Review

World journal of … 2017 68 atıf

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Meta-Analysis

Journal of pediatric … 2016 233 atıf

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Review

Clinical and experimental … 2016 82 atıf

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Other

Open forum infectious … 2016 58 atıf

Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Review

Antibiotics (Basel, Switzerland) 2015 104 atıf

Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Review

Nutrition in clinical … 2015 31 atıf

Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. RCT

The American journal … 2012 104 atıf

Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use. Other

The American journal … 2012 5 atıf

Probiotics for prevention and treatment of diarrhea. Review

Journal of clinical … 2011 432 atıf

Probiotics. Review

American journal of … 2010

Probiotics as prevention and treatment for diarrhea. Review

Current opinion in … 2009 82 atıf

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Meta-Analysis

The American journal … 2006 918 atıf

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Review

Journal of clinical … 2006 112 atıf

Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. RCT

Medical science monitor … 2006

Protection from gastrointestinal diseases with the use of probiotics. Review

The American journal … 2001 648 atıf

Treatment and prevention of antibiotic associated diarrhea. Review

International journal of … 2000 181 atıf

Mechanisms and management of antibiotic-associated diarrhea. Review

Clinical infectious diseases … 1998 346 atıf

Pharmaceutical probiotics for the treatment of anaerobic and other infections. Other

Anaerobe 1997 40 atıf

Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. CCT

Gastroenterology 1989 418 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

general:: 250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:: 500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:: 500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:: 250-500 mg/day starting 5 days before travel

Üst sınır: Well-tolerated up to 1,000 mg/day in clinical trials

Araştırmalarda İncelenen Dozajlar

Dozaj	Süre	Etki	N
None	--	Mixed	--
None	--	Positive	--
None	520 weeks	Positive	--
None	--	Mixed	--
None	--	Mixed	228
None	--	Mixed	--
None	--	Mixed	--
None	--	Mixed	--

En iyi alım zamanı: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

Bildirilen Yan Etkiler

⚠ Mild gas and bloating
⚠ Rare: fungemia in critically ill patients with central venous catheters
⚠ Thirst (yeast may increase water requirements)
⚠ Very rare: potential environmental contamination risk in ICU settings

Bilinen Etkileşimler

● Antifungal medications (may kill S. boulardii, reducing effectiveness)
● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

Tolere edilebilir üst alım: Well-tolerated up to 1,000 mg/day in clinical trials

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Saccharomyces boulardii help with Clostridioides difficile Infection (CDI)?

Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Clostridioides difficile Infection (CDI) management. Our evidence grade is B (Good Evidence).

How much Saccharomyces boulardii should I take for Clostridioides difficile Infection (CDI)?

Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Saccharomyces boulardii?

Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Saccharomyces boulardii and Clostridioides difficile Infection (CDI)?

We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

Related Evidence

Saccharomyces boulardii diğer sağlık durumları için

Antibiotic-Associated Diarrhea (AAD) A Traveler's Diarrhea B

Hızlı Değerlendirme

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

Evidence Strength72%

High confidence

Çalışma Dağılımı

RCT (2)Meta (2)Other (2)

Alternatifleri Karşılaştır

Bu durum için diğer bileşenlerin nasıl karşılaştırıldığını görün.Diğer içeriklerin bu sağlık durumu için nasıl karşılaştırıldığını görün.

Şu durum için tüm içerikleri görüntüle: Clostridioides difficile Infection (CDI)

Daha Fazla Bilgi

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.